Money is flowing into cannabis equities at a pace this sector hasn't seen in years, and the numbers back it up. The AdvisorShares Pure US Cannabis ETF (MSOS) posted a 103.7% one-year net asset value return as of May 31, more than double the North American Marijuana Index's 36.9% gain and well ahead of the S&P 500's 29.8%. Over just the past three months, MSOS climbed 28% while the broader marijuana benchmark actually slipped about 1%, a divergence that tells you this rally is concentrated, not sector-wide.
What's driving the concentration is a mix of policy momentum and structural change inside individual companies. Trulieve Cannabis, MSOS' largest holding at roughly 30% of assets, began trading on the NYSE under the ticker TRLV, a listing CEO Kim Rivers called a historic milestone. The company reorganized its corporate structure, separating medical cannabis operations from adult-use businesses, a move that cleared the compliance bar for a senior exchange listing. For operators watching from the sidelines, this is the kind of back-office restructuring that rarely makes headlines but determines whether a company can access institutional capital at all; the same operational discipline that shows up in a state-licensed operator's use of cannabis dispensary management software arizona for inventory and compliance tracking scales up, in a much more complex form, when a multi-state operator prepares for a stock exchange listing. cannabis dispensary management software arizona
Why the DEA Hearing Carries Weight
The administrative hearing scheduled for June 29, expected to run through mid-July, will examine whether cannabis products beyond medical use should move to Schedule III. That question matters enormously to operators' bottom lines. Acting Attorney General Todd Blanche already moved state-licensed medical marijuana products into Schedule III in April, a step that eliminated a specific tax penalty for licensed medical operators. Under Section 280E of the federal tax code, cannabis businesses have long been barred from deducting ordinary expenses like payroll, rent, and interest because the substance remains federally controlled. Schedule III reclassification for medical products removed that penalty for those operators; a broader rescheduling covering adult-use cannabis would extend that relief across the industry, materially changing what operators keep after tax.
Trump's formal nomination of Blanche to serve as permanent attorney general adds another layer of investor confidence that the rescheduling track stays on course rather than stalling under new leadership.
What Rescheduling Would Actually Change for Operators
AdvisorShares has pointed to earnings, free cash flow, and balance-sheet improvements as likely outcomes, along with better access to banking services and institutional capital - areas where cannabis retail has been chronically underserved compared with conventional retail. Roth Capital described the rescheduling order as extremely favorable for taxation, capital access, and future uplistings. That last point is already playing out. Cresco Labs secured a $50 million revolving credit facility from Needham Bank this week, financing CEO Charlie Bachtell described as a non-dilutive tool to fund acquisitions while positioning the company for U.S. capital markets access and an eventual senior exchange listing. Tilray Brands, though not part of MSOS, has signaled it may deploy proceeds from its at-the-market program toward acquisitions tied to the same reform expectations.
Here's the catch for anyone reading these gains as a straight line up: reclassification isn't legalization, and it doesn't resolve interstate commerce restrictions, state-by-state license caps, or the patchwork of compliant packaging and lab-testing rules operators still have to manage daily. A hearing outcome favorable to rescheduling would ease tax and banking pressure - it would not simplify the seed-to-sale tracking, METRC reporting, or wholesale pricing compliance that dispensaries and multi-state operators handle at the store level every day.
Where the Market Sees Upside - and Risk
Among MSOS holdings, Verano carries the highest analyst upside at roughly 195%, followed by Jushi Holdings near 183% and Cresco Labs close to 99%. Green Thumb Industries, at 70% upside, stands out among the larger positions, ahead of both Trulieve and Curaleaf, the world's largest cannabis company by revenue. Glass House is the outlier with a projected downside near 22%, a reminder that not every name in the ETF is riding the same wave.
Retail sentiment on platforms like Stocktwits runs extremely bullish for MSOS, Trulieve, and Green Thumb, with high message volume across the board. That kind of retail enthusiasm is worth watching critically rather than following blindly. Price targets and analyst upside figures reflect assumptions about a rescheduling outcome that hasn't happened yet. For dispensary operators, suppliers, and compliance teams, the more durable story isn't the stock chart - it's whether the tax and banking relief actually reaches the balance sheet, and whether the operational backbone of compliant, well-run retail keeps pace with the capital now circling the sector.
